Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Talphera, Inc. (TLPH)
USD1.43
+0.03 (+1.86%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
1850 Gateway Drive 94404
San Mateo, CA, US
San Mateo, CA, US
CEO
Vincent J. Angotti
Website
talphera.com
IPO
2011-02-11
CIK 1427925 ISIN US00444T2096
Also trades on
NASDAQ Global Market · ACRX (USD)
NASDAQ Global Market · TLPH (USD)
Description
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.43
+0.03 (+1.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
180.4K
Beta
0.76
Float Shares
12.76M
Free Float %
62.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.15% | -2.35% | +10.16% | +5.76% | -18.33% | -24.78% | +64.94% | +8.54% | -95.84% | -98.66% | -99.06% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
1.43
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-22.25
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%— Q1'26: -100.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+32.0% ★ Q1'26: +59.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-44,292.9%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-48,157.1%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-427.7% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+64.1% Q1'26: +165.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.48× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.26M
est: 22.51M (-14.4%)
|
17.36M
est: 13.85M (+25.3%)
|
8.00M
est: 12.50M (-36.0%)
|
2.15M
est: 2.90M (-25.9%)
|
2.29M
est: 2.81M (-18.5%)
|
5.42M
est: 6.20M (-12.6%)
|
378.0K
est: 4.66M (-91.9%)
|
—
est: 6.01M (-100.0%)
|
651.0K
est: 651.0K (+0.0%)
|
—
est: 1.37M (-100.0%)
|
28.0K
est: 27.0K (+3.7%)
|
3.95M
3.95M – 3.95M
+14,533.3% YoY
|
1.78M
1.78M – 1.78M
-54.9% YoY
|
11.51M
11.51M – 11.51M
+546.0% YoY
|
27.05M
27.05M – 27.05M
+135.0% YoY
|
50.44M
50.44M – 50.44M
+86.5% YoY
|
| EBITDA |
-16.25M
est: -4.50M (-260.9%)
|
-28.99M
est: -2.77M (-946.5%)
|
-36.43M
est: -2.50M (-1,357.1%)
|
-34.01M
est: -580.3K (-5,761.7%)
|
-49.03M
est: -561.7K (-8,630.2%)
|
-35.22M
est: -1.24M (-2,740.1%)
|
-16.14M
est: -931.6K (-1,632.8%)
|
61.90M
est: -1.20M (+5,250.3%)
|
-16.79M
est: -130.2K (-12,797.9%)
|
-15.16M
est: -273.0K (-5,451.7%)
|
-13.48M
est: -5.4K (-249,650.0%)
|
-790.2K
-790.2K – -790.2K
-14,536.0% YoY
|
-356.3K
-356.3K – -356.3K
+54.9% YoY
|
-2.30M
-2.30M – -2.30M
-546.0% YoY
|
-5.41M
-5.41M – -5.41M
-135.0% YoY
|
-10.09M
-10.09M – -10.09M
-86.5% YoY
|
| EBIT |
-18.23M
est: -4.50M (-305.0%)
|
-31.04M
est: -2.77M (-1,020.6%)
|
-38.17M
est: -2.50M (-1,426.9%)
|
-34.59M
est: -580.3K (-5,860.8%)
|
-50.70M
est: -561.7K (-8,927.2%)
|
-37.07M
est: -1.24M (-2,889.5%)
|
-18.12M
est: -931.6K (-1,844.6%)
|
60.25M
est: -1.20M (+5,113.2%)
|
-16.89M
est: -130.2K (-12,871.7%)
|
-15.25M
est: -273.0K (-5,486.8%)
|
-13.48M
est: -5.4K (-249,650.0%)
|
-790.2K
-790.2K – -790.2K
-14,536.0% YoY
|
-356.3K
-356.3K – -356.3K
+54.9% YoY
|
-2.30M
-2.30M – -2.30M
-546.0% YoY
|
-5.41M
-5.41M – -5.41M
-135.0% YoY
|
-10.09M
-10.09M – -10.09M
-86.5% YoY
|
| Net Income |
-24.40M
est: -246.05M (+90.1%)
|
-43.16M
est: -500.37M (+91.4%)
|
-51.51M
est: -516.91M (+90.0%)
|
-47.15M
est: -421.93M (+88.8%)
|
-53.24M
est: -356.26M (+85.1%)
|
-40.38M
est: -246.83M (+83.6%)
|
-35.10M
est: -149.90M (+76.6%)
|
42.52M
est: 179.63M (-76.3%)
|
-18.40M
est: -34.24M (+46.3%)
|
-13.00M
est: -25.02M (+48.0%)
|
-14.29M
est: -15.06M (+5.1%)
|
-11.73M
-11.73M – -11.73M
+22.1% YoY
|
-8.91M
-11.13M – -6.68M
+24.1% YoY
|
-7.94M
-9.59M – -1.44M
+10.9% YoY
|
1.48M
1.48M – 1.48M
+118.7% YoY
|
10.39M
10.39M – 10.39M
+600.0% YoY
|
| SGA |
14.20M
est: 39.20M (-63.8%)
|
15.60M
est: 24.12M (-35.3%)
|
16.61M
est: 21.77M (-23.7%)
|
20.77M
est: 5.05M (+310.9%)
|
45.03M
est: 4.89M (+820.6%)
|
36.33M
est: 10.80M (+236.5%)
|
—
est: 8.11M (-100.0%)
|
17.01M
est: 10.47M (+62.5%)
|
—
est: 35.04M (-100.0%)
|
—
est: 73.47M (-100.0%)
|
7.48M
est: 1.45M (+414.7%)
|
212.65M
212.65M – 212.65M
+14,533.3% YoY
|
95.88M
95.88M – 95.88M
-54.9% YoY
|
619.43M
619.43M – 619.43M
+546.0% YoY
|
1.46B
1.46B – 1.46B
+135.0% YoY
|
2.71B
2.71B – 2.71B
+86.5% YoY
|
| EPS |
-11.93
est: -9.52 (-25.3%)
|
-19.05
est: -19.36 (+1.6%)
|
-21.97
est: -20.00 (-9.8%)
|
-16.14
est: -16.33 (+1.1%)
|
-13.45
est: -13.78 (+2.4%)
|
-9.47
est: -9.55 (+0.8%)
|
-5.86
est: -5.80 (-1.0%)
|
5.73
est: 6.95 (-17.6%)
|
-1.29
est: -0.81 (-59.8%)
|
-0.50
est: -0.59 (+15.3%)
|
-0.34
est: -0.36 (+4.2%)
|
-0.28
-0.28 – -0.28
+22.1% YoY
|
-0.21
-0.26 – -0.16
+24.1% YoY
|
-0.13
-0.23 – -0.03
+38.1% YoY
|
0.04
0.04 – 0.04
+126.9% YoY
|
0.25
0.25 – 0.25
+600.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-12.02M
OE per share TTM
-0.35
Owner's Yield
-33.04%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
815.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
4.60M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-33 vs prev Q
New positions
3
Closed positions
30
Increased
8
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EMPERY ASSET MANAGEMENT, LP | 1.33M +1.3M (+100.0%) | 1.52B +1.5B (+100.0%) | 3.22% +3.217 pp | 1.34% +1.341 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 2 | AIGH CAPITAL MANAGEMENT LLC | 4.66M +207.0K (+4.6%) | 5.31M +1.3M (+33.6%) | 11.25% -1.655 pp | 1.29% +0.165 pp | USD0.90 +26.7% | 2 qtrs — |
| 3 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 3.59M +— (+0.0%) | 4.09M +885.8K (+27.6%) | 8.66% -1.736 pp | 0.21% +0.023 pp | USD1.01 +12.9% | 13 qtrs — |
| 4 | ROSALIND ADVISORS, INC. | 3.58M -806.5K (-18.4%) | 4.08M +163.0K (+4.2%) | 8.63% -4.067 pp | 1.43% +0.095 pp | USD0.75 +52.0% | 9 qtrs — |
| 5 | NANTAHALA CAPITAL MANAGEMENT, LLC | 3.49M +— (+0.0%) | 3.98M +862.0K (+27.6%) | 8.43% -1.689 pp | 0.13% +0.023 pp | USD0.82 +39.0% | 10 qtrs — |
| 6 | BLEICHROEDER LP | 881.2K +— (+0.0%) | 1.00M +217.5K (+27.6%) | 2.13% -0.426 pp | 0.18% +0.023 pp | USD0.70 +62.9% | 4 qtrs — |
| 7 | CAPTION MANAGEMENT, LLC | 799.6K +549.6K (+219.8%) | 911.5K +688.2K (+308.2%) | 1.93% +1.205 pp | 0.01% +0.005 pp | USD1.06 +7.5% | 2 qtrs — |
| 8 | VANGUARD GROUP INC | 663.7K +377.4K (+131.9%) | 756.6K +499.8K (+194.7%) | 1.60% +0.772 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 13 qtrs — |
| 9 | DAUNTLESS INVESTMENT GROUP, LLC | 579.3K +479.3K (+479.3%) | 660.4K +571.1K (+639.4%) | 1.40% +1.108 pp | 0.52% +0.469 pp | USD1.10 +3.6% | 2 qtrs — |
| 10 | CANTOR FITZGERALD, L. P. | 577.5K +577.5K (+100.0%) | 658.3K +658.3K (+100.0%) | 1.39% +1.393 pp | 0.01% +0.010 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 343.0K +177.3K (+107.0%) | 391.1K +242.4K (+163.0%) | 0.83% +0.348 pp | 0.00% +0.000 pp | USD1.18 -3.4% | 13 qtrs — |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 257.4K +207.2K (+412.6%) | 293.4K +248.6K (+554.2%) | 0.62% +0.476 pp | 0.00% +0.000 pp | USD1.06 +7.5% | 5 qtrs — |
| 13 | DIADEMA PARTNERS LP | 136.9K +136.9K (+100.0%) | 156.1K +156.1K (+100.0%) | 0.33% +0.330 pp | 0.03% +0.027 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 14 | BLACKROCK, INC. | 91.5K +— (+0.0%) | 104.4K +22.6K (+27.6%) | 0.22% -0.044 pp | 0.00% +0.000 pp | USD0.86 +32.6% | 6 qtrs — |
| 15 | SIMPLEX TRADING, LLC | 85.8K +84.6K (+6,892.6%) | 97.8K +96.8K (+9,681.0%) | 0.21% +0.203 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 2 qtrs — |
| 16 | JANE STREET GROUP, LLC | 84.9K +84.9K (+100.0%) | 96.8K +96.8K (+100.0%) | 0.20% +0.205 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 17 | VALUES FIRST ADVISORS, INC. | 81.2K -16.7K (-17.0%) | 92.6K +5.1K (+5.9%) | 0.20% -0.088 pp | 0.05% +0.001 pp | USD1.35 -15.6% | 13 qtrs — |
| 18 | CITADEL ADVISORS LLC | 76.4K +76.4K (+100.0%) | 87.1K +87.1K (+100.0%) | 0.18% +0.184 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 19 | MARINER, LLC | 58.0K +33.0K (+132.0%) | 66.1K +43.8K (+196.1%) | 0.14% +0.068 pp | 0.00% +0.000 pp | USD1.03 +10.7% | 2 qtrs — |
| 20 | GROUP ONE TRADING, L.P. | 57.2K +26.8K (+88.0%) | 65.2K +37.9K (+138.9%) | 0.14% +0.050 pp | 0.00% +0.000 pp | USD1.01 +12.9% | 9 qtrs — |
| 21 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 56.4K +56.4K (+100.0%) | 64.3K +64.3K (+100.0%) | 0.14% +0.136 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 22 | NORTHERN TRUST CORP | 52.6K +41.7K (+382.8%) | 59.9K +50.2K (+516.2%) | 0.13% +0.095 pp | 0.00% +0.000 pp | USD1.37 -16.8% | 13 qtrs — |
| 23 | PERSISTENT ASSET PARTNERS LTD | 36.6K +36.6K (+100.0%) | 41.8K +41.8K (+100.0%) | 0.09% +0.088 pp | 0.02% +0.019 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 24 | TWO SIGMA INVESTMENTS, LP | 24.6K +24.6K (+100.0%) | 28.0K +28.0K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 25 | STATE STREET CORP | 22.2K +— (+0.0%) | 25.3K +5.4K (+27.1%) | 0.05% -0.011 pp | 0.00% +0.000 pp | USD2.26 -49.6% | 13 qtrs — |
| 26 | GSA CAPITAL PARTNERS LLP | 21.0K +21.0K (+100.0%) | 24.0K +24.0K (+100.0%) | 0.05% +0.051 pp | 0.00% +0.002 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 27 | ONYX BRIDGE WEALTH GROUP LLC | 11.5K +— (+0.0%) | 13.1K +2.8K (+27.6%) | 0.03% -0.006 pp | 0.00% +0.000 pp | USD0.54 +111.1% | 4 qtrs — |
| 28 | UBS GROUP AG | 6.8K -20.8K (-75.3%) | 7.8K -16.9K (-68.5%) | 0.02% -0.064 pp | 0.00% +0.000 pp | USD0.89 +28.1% | 13 qtrs — |
| 29 | MAI CAPITAL MANAGEMENT | 3.3K +— (+0.0%) | 3.8K +817.0 (+27.6%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD1.07 +6.5% | 8 qtrs — |
| 30 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.8K -3.4K (-54.5%) | 3.2K -2.3K (-42.0%) | 0.01% -0.011 pp | 0.00% 0.000 pp | USD1.08 +5.6% | 13 qtrs — |
| 31 | WELLS FARGO & COMPANY/MN | 983.00 +500.0 (+103.5%) | 1.1K +690.0 (+160.1%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.66 -31.3% | 13 qtrs — |
| 32 | BANK OF AMERICA CORP /DE/ | 335.00 +159.0 (+90.3%) | 382.00 +225.0 (+143.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.94 +21.3% | 9 qtrs — |
| 33 | SILICON VALLEY CAPITAL PARTNERS | 137.00 +— (+0.0%) | 156.00 +34.0 (+27.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.26 -49.6% | 13 qtrs — |
| 34 | BNP PARIBAS ARBITRAGE, SNC | 136.00 +— (+0.0%) | 155.00 +34.0 (+28.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.52 +119.2% | 5 qtrs — |
| 35 | SRS CAPITAL ADVISORS, INC. | 81.00 +81.0 (+100.0%) | 92.00 +92.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 36 | SBI SECURITIES CO., LTD. | 78.00 -175.0 (-69.2%) | 89.00 -137.0 (-60.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD0.51 +123.5% | 5 qtrs — |
| 37 | GLOBAL RETIREMENT PARTNERS, LLC | 23.00 -50.0 (-68.5%) | 26.00 -39.0 (-60.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.43 +165.1% | 3 qtrs — |
| 38 | MORGAN STANLEY | 10.00 +— (+0.0%) | 11.00 +2.0 (+22.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +128.0% | 13 qtrs — |
| 39 | DOGWOOD WEALTH MANAGEMENT LLC | 10.00 +— (+0.0%) | 11.00 +2.0 (+22.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +128.0% | 5 qtrs — |
| 40 | ADVISOR GROUP HOLDINGS, INC. | — -26.0 (-100.0%) | — -14.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
| 41 | NEWEDGE ADVISORS, LLC | — -500.0 (-100.0%) | — -447.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
| 42 | STERLING CAPITAL MANAGEMENT LLC | — -2.0K (-100.0%) | — -1.8K (-100.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 43 | CITIGROUP INC | — -1.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 44 | BARCLAYS PLC | — -11.0 (-100.0%) | — -9.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 45 | VIRTU FINANCIAL LLC | — -32.8K (-100.0%) | — -29.0K (-100.0%) | 0.00% -0.095 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 46 | PFG INVESTMENTS, LLC | — -10.0K (-100.0%) | — -8.9K (-100.0%) | 0.00% -0.029 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 351.0K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
4
Shares acquired
—
Shares disposed
16.9K
Cash buys
—
Cash sales
—
Net activity
-16,944
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Dasu Badri N | Officer | F-InKind | D | Common Stock | 2,444 | 0.72 | 1.8K | 71,440 | D | ↗ |
| 2026-04-02 | Aslam Shakil | Officer | F-InKind | D | Common Stock | 2,118 | 0.72 | 1.5K | 81,060 | D | ↗ |
| 2026-04-02 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 9,938 | 0.72 | 7.2K | 790,767 | D | ↗ |
| 2026-04-02 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 2,444 | 0.72 | 1.8K | 85,879 | D | ↗ |
| 2026-03-13 | Nantahala Capital Management, LLC | 10% Owner | A-Award | A | Pre-Funded Warrants | 4,266,211 | 0.00 | 4.3K | 18,822,267 | I | ↗ |
| 2026-03-13 | Angotti Vincent J. | Director / Officer | P-Purchase | A | Common Stock | 213,310 | 0.59 | 125.0K | 800,705 | D | ↗ |
| 2026-02-14 | Dasu Badri N | Officer | F-InKind | D | Common Stock | 2,346 | 0.79 | 1.9K | 73,884 | D | ↗ |
| 2026-02-14 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 9,559 | 0.79 | 7.6K | 577,395 | D | ↗ |
| 2026-02-14 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 2,933 | 0.79 | 2.3K | 88,323 | D | ↗ |
| 2026-02-12 | Dasu Badri N | Officer | P-Purchase | A | Common Stock | 35,000 | 0.81 | 28.4K | 76,230 | D | ↗ |
| 2026-02-12 | Aslam Shakil | Officer | P-Purchase | A | Common Stock | 35,000 | 0.81 | 28.4K | 83,178 | D | ↗ |
| 2026-02-12 | Angotti Vincent J. | Director / Officer | P-Purchase | A | Common Stock | 105,364 | 0.81 | 85.6K | 586,954 | D | ↗ |
| 2026-02-12 | ASADORIAN RAFFI | Officer | P-Purchase | A | Commom Stock | 45,000 | 0.81 | 36.6K | 91,256 | D | ↗ |
| 2026-02-10 | Dasu Badri N | Officer | F-InKind | D | Common Stock | 781 | 0.84 | 652.99 | 41,230 | D | ↗ |
| 2026-02-10 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 3,179 | 0.84 | 2.7K | 481,590 | D | ↗ |
| 2026-02-10 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 958 | 0.84 | 800.98 | 46,256 | D | ↗ |
| 2025-10-23 | WAN MARK A | Director | A-Award | A | Common Stock | 4,267 | 0.00 | — | 8,859 | D | ↗ |
| 2025-10-23 | JAIN ABHINAV | Director | A-Award | A | Common Stock | 4,267 | 0.00 | — | 7,312 | D | ↗ |
| 2025-10-23 | HOFFMAN STEPHEN J | Director | A-Award | A | Common Stock | 4,267 | 0.00 | — | 8,859 | D | ↗ |
| 2025-10-23 | Broadfoot Jill Marie | Director | A-Award | A | Stock Option (Right to Buy) | 25,600 | 1.14 | 29.2K | 25,600 | D | ↗ |
| 2025-10-23 | Bozilenko Marina | Director | A-Award | A | Common Stock | 4,267 | 0.00 | — | 9,047 | D | ↗ |
| 2025-10-23 | ADAMS ADRIAN | Director | A-Award | A | Common Stock | 4,267 | 0.00 | — | 17,609 | D | ↗ |
| 2025-10-15 | Todisco Joseph | Director | A-Award | A | Director Stock Option (right to buy) | 38,381 | 1.11 | 42.6K | 38,381 | D | ↗ |
| 2025-10-14 | Todisco Joseph | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-07 | CorMedix Inc. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 9,090,909 | D | ↗ |
| 2025-05-20 | Aslam Shakil | Officer | F-InKind | D | Commom Stock | 4,517 | 0.52 | 2.3K | 48,178 | D | ↗ |
| 2025-04-02 | Dasu Badri N | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 42,011 | D | ↗ |
| 2025-04-02 | Aslam Shakil | Officer | A-Award | A | Commom Stock | 15,000 | 0.00 | — | 52,695 | D | ↗ |
| 2025-04-02 | Angotti Vincent J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 365,000 | 0.58 | 212.8K | 365,000 | D | ↗ |
| 2025-04-02 | ASADORIAN RAFFI | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 47,214 | D | ↗ |
| 2025-03-31 | Nantahala Capital Management, LLC | 10% Owner | A-Award | A | Pre-Funded Warrants | 4,266,211 | 0.00 | 4.3K | 11,510,601 | I | ↗ |
| 2025-02-14 | Dasu Badri N | Officer | F-InKind | D | Common Stock | 2,644 | 0.67 | 1.8K | 27,011 | D | ↗ |
| 2025-02-14 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 10,575 | 0.67 | 7.1K | 190,459 | D | ↗ |
| 2025-02-14 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 3,245 | 0.67 | 2.2K | 32,214 | D | ↗ |
| 2025-02-11 | Dasu Badri N | Officer | F-InKind | D | Common stock | 880 | 0.62 | 545.60 | 29,655 | D | ↗ |
| 2025-02-11 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 3,517 | 0.62 | 2.2K | 201,034 | D | ↗ |
| 2025-02-11 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 1,060 | 0.62 | 657.20 | 35,459 | D | ↗ |
| 2025-02-10 | Dasu Badri N | Officer | F-InKind | D | Common Stock | 879 | 0.63 | 553.68 | 30,535 | D | ↗ |
| 2025-02-10 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 3,515 | 0.63 | 2.2K | 204,551 | D | ↗ |
| 2025-02-10 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 1,059 | 0.63 | 667.06 | 36,519 | D | ↗ |
| 2024-12-05 | Angotti Vincent J. | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.64 | 3.2K | 208,066 | D | ↗ |
| 2024-12-02 | ASADORIAN RAFFI | Officer | S-Sale | D | Common Stock | 155 | 0.77 | 118.89 | 37,578 | D | ↗ |
| 2024-11-27 | Angotti Vincent J. | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.73 | 3.6K | 203,066 | D | ↗ |
| 2024-10-01 | Aslam Shakil | Officer | — | — | Common Stock | 0 | 0.00 | — | 32,000 | D | ↗ |
| 2024-08-30 | Angotti Vincent J. | Director / Officer | P-Purchase | A | Common Stock | 7,260 | 1.05 | 7.6K | 198,066 | — | ↗ |
| 2024-06-24 | WAN MARK A | Director | A-Award | A | Common Stock | 2,174 | 0.00 | — | 4,592 | — | ↗ |
| 2024-06-24 | JAIN ABHINAV | Director | A-Award | A | Common Stock | 2,174 | 0.00 | — | 3,045 | — | ↗ |
| 2024-06-24 | HOFFMAN STEPHEN J | Director | A-Award | A | Stock Option (Right to Buy) | 13,044 | 0.89 | 11.5K | 13,044 | — | ↗ |
| 2024-06-24 | Broadfoot Jill Marie | Director | A-Award | A | Common Stock | 2,174 | 0.00 | — | 4,280 | — | ↗ |
| 2024-06-24 | Bozilenko Marina | Director | A-Award | A | Common Stock | 2,174 | 0.00 | — | 4,780 | — | ↗ |
| 2024-06-24 | ADAMS ADRIAN | Director | A-Award | A | Stock Option (Right to Buy) | 13,044 | 0.89 | 11.5K | 13,044 | — | ↗ |
| 2024-06-14 | Aslam Shakil | Officer | P-Purchase | A | Common Stock | 5,000 | 1.07 | 5.4K | 37,695 | D | ↗ |
| 2024-06-14 | Angotti Vincent J. | Director / Officer | P-Purchase | A | Common Stock | 1,304 | 1.08 | 1.4K | 180,806 | — | ↗ |
| 2024-06-13 | Aslam Shakil | Officer | P-Purchase | A | Common Stock | 695 | 0.98 | 681.10 | 32,695 | D | ↗ |
| 2024-06-13 | Angotti Vincent J. | Director / Officer | P-Purchase | A | Common Stock | 4,570 | 0.97 | 4.4K | 179,502 | — | ↗ |
| 2024-06-12 | Angotti Vincent J. | Director / Officer | P-Purchase | A | Common Stock | 4,126 | 0.97 | 4.0K | 174,932 | — | ↗ |
| 2024-03-19 | Nantahala Capital Management, LLC | 10% Owner | J-Other | A | 2024 Pre-Funded Warrants | 324,675 | 0.00 | 324.68 | 6,493,507 | — | ↗ |
| 2024-03-15 | Nantahala Capital Management, LLC | 10% Owner | X-InTheMoney | A | Common Stock | 755,000 | 5.00 | 3.78M | 1,992,519 | — | ↗ |
| 2024-03-12 | Angotti Vincent J. | Director / Officer | A-Award | A | Common Stock | 8,000 | 1.12 | 9.0K | 170,806 | — | ↗ |
| 2024-03-11 | Angotti Vincent J. | Director / Officer | A-Award | A | Common Stock | 1,000 | 1.12 | 1.1K | 162,806 | — | ↗ |
| 2024-03-03 | Palmer Pamela P | Officer | F-InKind | D | Common Stock | 450 | 1.30 | 585.00 | 59,149 | — | ↗ |
| 2024-03-03 | Dasu Badri N | Officer | F-InKind | D | Common Stock | 406 | 1.30 | 527.80 | 31,414 | — | ↗ |
| 2024-03-03 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 1,623 | 1.30 | 2.1K | 161,806 | — | ↗ |
| 2024-03-03 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 558 | 1.30 | 725.40 | 37,733 | — | ↗ |
| 2024-02-14 | Palmer Pamela P | Director / Officer | A-Award | A | Common Stock | 18,000 | 0.00 | — | 53,344 | — | ↗ |
| 2024-02-14 | Dasu Badri N | Officer | A-Award | A | Stock Option (Right to Buy) | 88,000 | 1.03 | 90.6K | 88,000 | — | ↗ |
| 2024-02-14 | Angotti Vincent J. | Director / Officer | A-Award | A | Common Stock | 58,667 | 0.00 | — | 153,429 | — | ↗ |
| 2024-02-14 | ASADORIAN RAFFI | Officer | A-Award | A | Common Stock | 18,000 | 0.00 | — | 38,291 | — | ↗ |
| 2024-02-11 | Palmer Pamela P | Director / Officer | F-InKind | D | Common Stock | 801 | 1.10 | 881.10 | 35,344 | — | ↗ |
| 2024-02-11 | Dasu Badri N | Officer | F-InKind | D | Common Stock | 809 | 1.10 | 889.90 | 17,153 | — | ↗ |
| 2024-02-11 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 3,723 | 1.10 | 4.1K | 94,762 | — | ↗ |
| 2024-02-11 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 895 | 1.10 | 984.50 | 20,291 | — | ↗ |
| 2024-02-10 | Palmer Pamela P | Director / Officer | F-InKind | D | Common Stock | 801 | 1.10 | 881.10 | 36,145 | — | ↗ |
| 2024-02-10 | Dasu Badri N | Officer | F-InKind | D | Common Stock | 809 | 1.10 | 889.90 | 17,962 | — | ↗ |
| 2024-02-10 | Angotti Vincent J. | Director / Officer | F-InKind | D | Common Stock | 3,320 | 1.10 | 3.7K | 98,485 | — | ↗ |
| 2024-02-10 | ASADORIAN RAFFI | Officer | F-InKind | D | Common Stock | 895 | 1.10 | 984.50 | 21,186 | — | ↗ |
| 2024-01-22 | Nantahala Capital Management, LLC | 10% Owner | D-Return | D | 2023 Series B Warrants | 2,205,883 | 1.11 | 2.45M | 0 | — | ↗ |
| 2024-01-22 | JAIN ABHINAV | Director | A-Award | A | Stock Option (Right to Buy) | 5,228 | 0.91 | 4.8K | 5,228 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.4K
Shares Outstanding
20.52M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Vincent J. Angotti Chief Executive Officer | 688.8K | 206.6K | 35.6K | 172.3K | — | 14.0K | 1.12M | 18.60% | ↗ |
| 2 | 2025 | Raffi Asadorian Chief Financial Officer | 520.9K | 145.9K | 8.7K | 37.8K | — | 14.0K | 727.3K | 6.39% | ↗ |
| 3 | 2025 | Shakil Aslam, M.D. Chief Medical Officer | 473.2K | 121.1K | 8.7K | 37.8K | — | 14.0K | 654.8K | 7.10% | ↗ |
| 4 | 2024 | Vincent J. Angotti Chief Executive Officer | 668.7K | — | 60.4K | 296.0K | — | 13.8K | 1.04M | 34.31% | ↗ |
| 5 | 2024 | Raffi Asadorian Chief Financial Officer | 505.8K | 80.9K | 18.5K | 90.8K | — | 13.8K | 709.9K | 15.41% | ↗ |
| 6 | 2024 | Shakil Aslam, M.D. Chief Medical Officer | 281.2K | 45.5K | 34.6K | 163.4K | — | 4.6K | 529.2K | 37.40% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vincent J. Angotti | Chief Executive Officer & Director | 909.5K | male |
| Raffi Mark Asadorian | Chief Financial Officer | 680.8K | male |
| Shakil Aslam | Chief Medical Officer | 608.3K | — |
| Anil N. Dasu | Chief Engineering Officer | 486.8K | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TLPH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
